



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: 15th May 2026

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 531569

Sub: Press Release on Audited Financial Results (Standalone and Consolidated) for the Fourth Quarter and Financial Year ended March 31, 2026.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release on the Audited Financial Results (Standalone and Consolidated) for the Fourth Quarter and Financial Year ended March 31, 2026.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam
Company Secretary Cum Compliance Officer



Sanjivani Parenteral Limited Reports FY26 Full-Year Results; EBITDA stood at ₹ 114 mn with PAT at ₹ 66.94 mn

Mumbai, 15th May, 2026: Sanjivani Parenteral Limited (Sanjivani, The Company) (BSE: 531569), one of the emerging players in the pharmaceutical and healthcare manufacturing sector, continued to strengthen its operational performance during the year through improved efficiencies, focused execution, and a customer-centric approach across its business segments, and has announced its Audited Financial Results for Q4 FY26.

Key Consolidated Financial Highlights

Particulars (₹ mn)	Q4 FY26	FY26
Total Income	138.09	697.56
EBITDA	21.73	114.00
EBITDA Margin (%)	15.74%	16.34%
PAT	5.48	66.94
PAT Margin (%)	3.97%	9.60%
EPS (₹)	0.49	5.49

Q4 FY26:

- Revenue from operations at ₹ 132.13 mn.
- EBITDA margin stood at 15.74%.
- PAT margin stood at 3.97%.

Segment-wise Performance:

- Injectables: Revenue stood at ₹46.70 mn, contributing 44.43% of revenue from operations.
- Tablets: Revenue grew by ~11.1% YoY to ₹54.60 mn, with contribution increasing to 51.95% of revenue from operations.
- Nutraceuticals: Revenue stood at ₹3.81 mn, accounting for 3.62% of revenue from operations.

Market-wise Performance:

- Exports (incl. incentives): Contributed 85.26% of revenue from operations (₹89.62 mn), while domestic accounted for 14.74%.
- Core markets (CIS, Middle East & Africa, Latin America): Contributed ~76.09% of revenue from operations, amounting to ~₹80.0 mn.

FY26:

- Revenue from operations grew at ₹ 686.66 mn.
- EBITDA margin stood at 16.34%.
- PAT margin stood at 9.60%.

Segment-wise Performance:

- Injectables: Revenue stood at ₹346.15 mn, contributing 53.45% of revenue from operations.
- Tablets: Revenue grew by Approx. 7.5% YoY to ₹279.14 mn, with contribution rising to 43.10% of revenue from operations.
- Nutraceuticals: Revenue stood at ₹22.35 mn, contributing 3.45% of revenue from operations.

Market-wise Performance:

- Exports (incl. incentives): Contributed 78.50% of revenue from operations (₹508 mn), while domestic contributed 21.50%.
- Core markets (CIS, Middle East & Africa, Latin America): Accounted for ~77.01% of revenue from operations, amounting to ~₹498.75 mn.

Commenting on the performance, Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Parenteral Limited said, “FY26 has been a year of steady operational progress and focused execution for Sanjivani Parenteral Limited. The commencement of commercial production at our newly established IV Fluid Infusion Plant in Pune marks a significant milestone in strengthening our manufacturing capabilities and expanding our healthcare product portfolio. Equipped with advanced technology and sustainable infrastructure, the facility is expected to improve operational efficiency, enhance product quality, and support growing demand across domestic and export markets.

Our continued focus on quality manufacturing, disciplined cost management, and long-term customer relationships has enabled us to maintain stable business performance in a dynamic operating environment. This expansion further strengthens our market presence and positions the Company for scalable and sustainable long-term growth as we move into FY27. We remain committed to evaluating new growth opportunities and strategic initiatives aimed at enhancing operational scale and creating long-term value for all stakeholders.”

About Sanjivani Parenteral Limited

Sanjivani Parenteral Limited (BSE: 531569) is engaged in the pharmaceutical and healthcare manufacturing business, with a focus on delivering quality products and maintaining strong operational standards. The Company continues to strengthen its presence through operational excellence, customer-centric execution, and continuous focus on quality and compliance.

With a commitment towards sustainable growth and long-term value creation, the Company continues to focus on enhancing manufacturing capabilities, improving efficiencies, and expanding its business presence across key markets.

For FY26, the company has reported Total Income of ₹ 697.56 mn, EBITDA of ₹ 114.00 mn & PAT of ₹ 66.94 mn on consolidated basis.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements.

The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal - Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com